Nu-Med Plus Reports Acquisition, Control Change, Equity Sales
Ticker: NUMD · Form: 8-K · Filed: Oct 30, 2024 · CIK: 1543637
| Field | Detail |
|---|---|
| Company | Nu-Med Plus, Inc. (NUMD) |
| Form Type | 8-K |
| Filed Date | Oct 30, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, change-of-control, equity-sale
TL;DR
Nu-Med Plus just filed an 8-K: acquisition done, control changed, sold some stock. Big moves happening.
AI Summary
Nu-Med Plus, Inc. filed an 8-K on October 30, 2024, reporting on several key events as of October 28, 2024. These include the completion of an acquisition or disposition of assets, unregistered sales of equity securities, a change in control of the registrant, and changes in directors and officers, including compensatory arrangements. The company is incorporated in Utah and its fiscal year ends on December 31.
Why It Matters
This filing indicates significant corporate actions, including a change in control and asset transactions, which could impact the company's strategic direction and shareholder value.
Risk Assessment
Risk Level: medium — The filing details a change in control and unregistered equity sales, which can introduce uncertainty and potential risks for investors.
Key Players & Entities
- Nu-Med Plus, Inc. (company) — Registrant
- October 28, 2024 (date) — Date of earliest event reported
- October 30, 2024 (date) — Filing date
- Utah (jurisdiction) — State of incorporation
FAQ
What specific assets were acquired or disposed of by Nu-Med Plus, Inc.?
The filing indicates the completion of an acquisition or disposition of assets, but the specific details of the assets involved are not provided in this summary.
What was the nature of the unregistered sales of equity securities?
The filing notes unregistered sales of equity securities occurred, but the terms, amount, and recipients of these sales are not detailed in this summary.
What triggered the change in control of Nu-Med Plus, Inc.?
The filing reports a change in control of the registrant, but the specific transaction or event causing this change is not elaborated upon in this summary.
Were there any changes to Nu-Med Plus, Inc.'s board of directors or executive officers?
Yes, the filing indicates changes in directors or certain officers, including their election and compensatory arrangements.
What is the business address of Nu-Med Plus, Inc.?
The business address of Nu-Med Plus, Inc. is 455 EAST 500 SOUTH, SUITE #203, SALT LAKE CITY, UT 84111.
Filing Stats: 679 words · 3 min read · ~2 pages · Grade level 9.8 · Accepted 2024-10-30 16:07:15
Filing Documents
- numd8-k102824.htm (8-K) — 24KB
- 0001548123-24-000118.txt ( ) — 191KB
- numd-20241028.xsd (EX-101.SCH) — 3KB
- numd-20241028_lab.xml (EX-101.LAB) — 33KB
- numd-20241028_pre.xml (EX-101.PRE) — 24KB
- numd8-k102824_htm.xml (XML) — 4KB
01 - COMPLETION OF ACQUISITION OR
ITEM 2.01 - COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS On April 28, 2024 Nu-Med Plus, Inc. ("Nu-Med") filed a Form 8-K regarding a Share Exchange Agreement entered into with YourSpace America, Inc. ("YourSpace") under which Nu-Med would receive all of the outstanding stock of YourSpace and YourSpace would receive stock in Nu-Med. The Share Exchange Agreement finalization was contingent upon YourSpace providing to Nu-Med audited financial statements for the years ended December 31, 2021, 2022 and 2023. YourSpace provided the audited financial statements for 2021 and 2022, but has not provided audited financial statements for 2023. It was therefore not possible to issue to YourSpace or its principals stock in Nu-Med Plus until such time as the audited financial statements were provided. On October 28, 2024, Nu-Med received notice from YourSpace that they were terminating the acquisition agreement.
02 - UNREGISTERED SALE OF SECURITIES
ITEM 3.02 - UNREGISTERED SALE OF SECURITIES The issuance of securities was contingent on the providing to Nu-Med Plus audited financial statements. As the audited financial statements were not provided, the stock exchange was not consummated. See Item 2.01 above.
01 – CHANGE IN CONTROL
ITEM 5.01 – CHANGE IN CONTROL No change in control took place, as the anticipated stock issuance was not consummated. See Item 2.01 above.
02 – DEPARTURE OF DIRECTORS OR CERTAIN
ITEM 5.02 – DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS Fully expecting the terms of the agreement to be met, Mr. Russ Colvin was appointed to be the President/Chief Executive Officer and a Director of Nu-Med. Accompanying the notice that YourSpace was terminating the transaction, Mr. Colvin submitted his resignation from the positions to which he had been appointed. On October 28, 2024, the Board of Directors appointed Mr. William Hayde, who is the Chairman of the Board, to serve as President/Chief Executive Officer of Nu-Med. William Hayde still serves as the Company's Executive Chairman of the Board and as a Director. Keith Merrell continues to serve as the Company's Chief Financial Officer and Director, and Jeffrey Robins continues to serve as Director.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized. NU-MED PLUS, INC. Date: October 30, 2024 By: /s/ William Hayde William Hayde President and Chief Executive Officer 2